How early is too early for lutetium PSMA in metastatic prostate cancer?
The data is evolving and comfort with the therapy is growing, but sequencing remains unsettled.
Should lutetium PSMA move forward in mCRPC while patients are fitter and disease burden may be lower? Or is its impact strongest when reserved for later lines, after AR targeted therapy and chemotherapy?
At #OLNGreatDebates, @kai_tsao, MD, MS, and @AtishChoudhury MD, PhD take opposing positions on when this therapy truly delivers the most value.
Hear both sides. Then decide where you stand.
Join us: https://t.co/MgHv2an7nc
#ProstateCancer #GUOncology #mCRPC
JUST IN: @US_FDA approved PARP inh Niraparib +abi/pred for BRCA2-mutated (BRCA2+) metastatic castration-sensitive prostate cancer (CSPC). Data based on AMPLITUDE trial showing rPFS benefit in the overall/BRCA population. Most benefit came from the BRCA2+ tumors: HR 0.46 (vs 0.88). Paper in @NatureMedicine led by @AttardLab @DRathkopf --Approval where therapies work Best!
Link: https://t.co/DgAuE5idLb
We are proud to share that The Mount Sinai Hospital's cancer service is ranked No. 8 in the nation by U.S. News & World Report® for 2024-25. @MountSinaiNYC
We are proud to announce that The Mount Sinai Hospital is ranked No. 12 in the nation for Cancer by U.S. News & World Report® for 2023-24.
@MountSinaiNYC@usnews